XRHealth acquires FDA-cleared fibromyalgia startup Swing Therapeutics
What's the deal? Medical virtual reality company XRHealth has acquired Swing Therapeutics, developer of a Food and Drug Administration-cleared digital treatment for fibromyalgia. Terms were not disclosed.
Why now? The purchase is XRHealth's sixth acquisition over the past two years. CEO Eran OrrDealroom has a profile for this one. Try Dealroom → said terms stayed private because "it won't be the last" deal for the company.
What's the endgame? The acquisition marks a new direction for XRHealth, which aims to become a go-to source of digital treatments for disease. Its platform already hosts dozens of apps spanning meditation and cognitive behavioural therapy-based VR experiences for mental health, pain, hot flashes, and more.
By the numbers: XRHealth delivered a million user sessions in 2025, according to Orr.
What could go wrong? Regulatory standing varies across the portfolio. XRHealth's large packages of VR treatments are registered with the FDA but not cleared, unlike Swing's fibromyalgia treatment.
The signal: A serial acquirer is consolidating digital therapeutics under one roof, betting that a broad menu of FDA-touched apps can position VR as a mainstream channel for treating disease.
Read more: STAT News
